Drug intelligence / Profile preview

REVO-UWD19

Development stage: Unknown
Lead developer: Shenzhen Wandao Cell Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

REVO-UWD19 is an investigational, off-the-shelf (universal) CAR-T cell therapy targeting CD19, developed by Wondercel Therapeutics. It is built on the REVO-U platform, which utilizes a gene-editing-free approach to prevent Graft-versus-Host Disease (GvHD) through protein-directed degradation of the T-cell receptor (TCR). This platform is designed for ultra-high-yield manufacturing, capable of producing over 3,000 doses from a single healthy donor batch. REVO-UWD19 is currently being evaluated in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on REVO-UWD19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REVO-UWD19.

Explore the full profile